Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mayuresh M. Abhyankar, Barbara J. Mann, Jeffrey M. Sturek, Savannah Brovero, G. Brett Moreau, Anjali Sengar, Crystal M. Richardson, Sayeh Agah, Anna Pomés, Peter M. Kasson, Mark A. Tomai, Christopher B. Fox, William A. Petri
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/da4da1c7c88a4956b31769225afbc2c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da4da1c7c88a4956b31769225afbc2c2
record_format	dspace
spelling	oai:doaj.org-article:da4da1c7c88a4956b31769225afbc2c22021-11-21T12:04:36ZDevelopment of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant10.1038/s41541-021-00399-02059-0105https://doaj.org/article/da4da1c7c88a4956b31769225afbc2c22021-11-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00399-0https://doaj.org/toc/2059-0105Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.Mayuresh M. AbhyankarBarbara J. MannJeffrey M. SturekSavannah BroveroG. Brett MoreauAnjali SengarCrystal M. RichardsonSayeh AgahAnna PomésPeter M. KassonMark A. TomaiChristopher B. FoxWilliam A. PetriNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mayuresh M. Abhyankar Barbara J. Mann Jeffrey M. Sturek Savannah Brovero G. Brett Moreau Anjali Sengar Crystal M. Richardson Sayeh Agah Anna Pomés Peter M. Kasson Mark A. Tomai Christopher B. Fox William A. Petri Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
description	Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
format	article
author	Mayuresh M. Abhyankar Barbara J. Mann Jeffrey M. Sturek Savannah Brovero G. Brett Moreau Anjali Sengar Crystal M. Richardson Sayeh Agah Anna Pomés Peter M. Kasson Mark A. Tomai Christopher B. Fox William A. Petri
author_facet	Mayuresh M. Abhyankar Barbara J. Mann Jeffrey M. Sturek Savannah Brovero G. Brett Moreau Anjali Sengar Crystal M. Richardson Sayeh Agah Anna Pomés Peter M. Kasson Mark A. Tomai Christopher B. Fox William A. Petri
author_sort	Mayuresh M. Abhyankar
title	Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_short	Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_full	Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_fullStr	Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_full_unstemmed	Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_sort	development of covid-19 vaccine using a dual toll-like receptor ligand liposome adjuvant
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/da4da1c7c88a4956b31769225afbc2c2
work_keys_str_mv	AT mayureshmabhyankar developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT barbarajmann developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT jeffreymsturek developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT savannahbrovero developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT gbrettmoreau developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT anjalisengar developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT crystalmrichardson developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT sayehagah developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT annapomes developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT petermkasson developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT markatomai developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT christopherbfox developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant AT williamapetri developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
_version_	1718419275007393792

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Ejemplares similares